Gene Editing’s Ascent: How CRISPR Is Reshaping Pharma’s Institutional Architecture
Gene editing is redirecting pharmaceutical capital toward modular, patient‑specific platforms, compelling regulators, manufacturers, and talent pipelines to restructure around a new model…










